X
ABBV icon

Xponance’s AbbVie ABBV Stock Holding History

Xponance’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$111M Buy
511,945
+32,393
+7% +$7.19M 0.79% 19
2025
Q4 		$110M Buy
479,552
+15,898
+3% +$3.62M 0.82% 15
2025
Q3 		$107M Buy
463,654
+12,379
+3% +$2.52M 0.85% 18
2025
Q2 		$83.8M Buy
451,275
+107,804
+31% +$20M 0.7% 19
2025
Q1 		$72M Buy
343,471
+4,597
+1% +$894K 0.7% 19
2024
Q4 		$60.2M Sell
338,874
-631
-0.2% -$116K 0.55% 24
2024
Q3 		$67M Buy
339,505
+6,919
+2% +$1.29M 0.65% 20
2024
Q2 		$57M Sell
332,586
-86,817
-21% -$14.4M 0.58% 23
2024
Q1 		$76.4M Buy
419,403
+6,803
+2% +$1.17M 0.8% 17
2023
Q4 		$63.9M Buy
412,600
+7,001
+2% +$1.02M 0.77% 18
2023
Q3 		$60.5M Buy
405,599
+3,109
+0.8% +$456K 0.82% 16
2023
Q2 		$54.2M Buy
402,490
+4,966
+1% +$728K 0.72% 17
2023
Q1 		$63.4M Buy
397,524
+8,004
+2% +$1.22M 0.93% 13
2022
Q4 		$63M Buy
389,520
+34,407
+10% +$5.28M 1.02% 12
2022
Q3 		$47.7M Buy
355,113
+25,491
+8% +$3.66M 0.92% 12
2022
Q2 		$50.5M Sell
329,622
-8,602
-3% -$1.31M 1.01% 11
2022
Q1 		$54.8M Buy
338,224
+28,895
+9% +$4.2M 0.91% 12
2021
Q4 		$41.9M Buy
309,329
+24,162
+8% +$2.85M 0.66% 21
2021
Q3 		$30.8M Sell
285,167
-50,291
-15% -$5.75M 0.58% 23
2021
Q2 		$37.8M Buy
335,458
+10,375
+3% +$1.17M 0.69% 16
2021
Q1 		$35.2M Sell
325,083
-136
-0% -$14.5K 0.75% 19
2020
Q4 		$34.8M Buy
325,219
+1,752
+0.5% +$168K 0.76% 19
2020
Q3 		$28.3M Sell
323,467
-17,198
-5% -$1.62M 0.7% 24
2020
Q2 		$33.4M Buy
+340,665
New +$30M 0.86% 18

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Xponance's ABBV Position: Q1 2026 in Review

Xponance increased its AbbVie (ABBV) stake by 6.8% in Q1 2026, buying an estimated $7.19M and bringing the position to 511,945 shares worth $111M. The position accounts for 0.79% of the portfolio, ranked #19.

Xponance first reported a position in ABBV in Q2 2020 and has held it in 24 quarters since. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Xponance held 511,945 shares of AbbVie worth $111M as of Q1 2026.
  • Xponance bought 32,393 AbbVie shares in Q1 2026, an estimated $7.19M.
  • AbbVie made up 0.79% of Xponance's portfolio in Q1 2026, its #19 holding.
  • Xponance first reported a position in AbbVie in Q2 2020 and has held it in 24 quarters since.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.